Investigating Imeglimin Safety and Efficacy in Patients with Type 2 Diabetes Mellitus During Fasting in Ramadan
Journal of Diabetology · 2026-05 · 17 (3) · 250-255
DOI: 10.4103/jod.jod_155_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetology, online erschienen am 22.05.2026. Verfasst von Hossam Arafa Ghazi und 1 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Fasting during Ramadan is a challenge for those with type 2 diabetes mellitus (T2DM). Imeglimin is a new oral antidiabetic medicine that works in two ways and has a minimal risk of causing hypoglycemia and/or hemodynamic changes. These advantages make imeglimin a possible choice for use during Ramadan.
Objective
The goal was to examine the safety and effectiveness of imeglimin versus vildagliptin in individuals with T2DM who were fasting during Ramadan. Materials and Methods: A total of 126 adults with T2DM were randomly assigned (1:1) to receive either imeglimin [1000 mg twice daily (BID)] or vildagliptin (50 mg BID), along with metformin. Changes in glycated hemoglobin (HbA1c) and the frequency of hypoglycemic and/or hyperglycemic episodes were the main outcomes. Patients were checked 4–6 weeks before and after Ramadan.
Results
After Ramadan, both groups had significant decreases in HbA1c. The imeglimin group had a bigger drop (14.2% vs. 7.5%; P < 0.001 between groups, P = 0.227 within groups). The imeglimin group had fewer hypoglycemic ( P = 0.02) and hyperglycemic episodes ( P = 0.001) during fasting. The body mass index decreased more in the imeglimin group ( P = 0.02) but not in the vildagliptin group ( P = 0.084). There were no clinically significant changes in liver enzymes or kidney function in either group.
Conclusion
Imeglimin and metformin together are a safe and effictive treatment for people with T2DM who are willing to fast during Ramadan.
Zitieren
APA
Ghazi, H. A., & Saboo, B. (2026). Investigating Imeglimin Safety and Efficacy in Patients with Type 2 Diabetes Mellitus During Fasting in Ramadan. Journal of Diabetology, 17(3), 250-255. https://doi.org/10.4103/jod.jod_155_25
Vancouver
Ghazi HA, Saboo B. Investigating Imeglimin Safety and Efficacy in Patients with Type 2 Diabetes Mellitus During Fasting in Ramadan. Journal of Diabetology. 2026;17(3):250-255. doi:10.4103/jod.jod_155_25
BibTeX
@article{Ghazi2026,
author = {Ghazi, Hossam Arafa and Saboo, Banshi},
title = {Investigating Imeglimin Safety and Efficacy in Patients with Type 2 Diabetes Mellitus During Fasting in Ramadan},
journal = {Journal of Diabetology},
year = {2026},
volume = {17},
number = {3},
pages = {250--255},
doi = {10.4103/jod.jod_155_25}
}
EUVIMED